
idea tx®
ENLIGHTENING ADVANCED THERAPIES
ENLIGHTENING
Advanced Therapies, accelerating access
END-TO-END
One partner, the whole pathway
ECOSYSTEM
Open innovation, GMP execution — an ecosystem built to scale ATMPs

A new light on the treatment of AGA

Androgenetic alopecia (AGA) is not just an aesthetic issue. Its progression leads to loss of the natural scalp UV protection covering, accelerates skin photoaging and increases the risk of melanoma. Beyond appearance, AGA can significantly affect self-esteem, anxiety, depression, and overall quality of life.

Driven by dihydrotestosterone (DHT), which activates androgen receptors in dermal papilla cells, the condition causes follicular miniaturization and progressive hair loss, worsened by damage to the follicle microenvironment due to oxidative stress, inflammation, and reduced vascularization.

In this context, IDEEEA Therapeutics presents AGAcell® therapy. **AGAcell®** is a proprietary and patented intradermal formulation that combines:

- **Allogeneic** GMP-grade **mesenchymal stem cells (MSCs).**
- **Adenosine triphosphate (ATP),** an energy-enhancing molecule with synergistic activity.

Formulated with a regenerative approach, this combination aims to restore the hair follicle microenvironment to reactivate its key functions and promote a sustained, healthy hair cycle.

AGAcell® How it works



AGAcell® at a glance

The challenge of AGA

Most AGA care depends on drugs and transplants. Medicines help while you take them — however benefits fade and side effects limit long-term use; surgery is invasive, costly and constrained by the donor area, often still needing medication. Patients are asking for **regenerative, durable** solutions.

Why MSCs? Why AGAcell®?

MSCs release trophic and immunomodulatory factors that help **restore the follicle niche** and support dermal papilla and microvasculature. A novel, safe, and minimally invasive regenerative therapeutic approach for AGA. In addition to MSCs, the formulation includes ATP which is a key molecule, that acts as an energy booster and whose synthesis is essential for maintaining a normal hair cycle and ensuring proper hair shaft formation.

Intellectual Property

- WO/2025/133317 “Composition for promoting hair growth”. Pending FFNN entry before June 2026.

AGACell® *highlights*

- ***Off-the-shelf***
- ***Allogeneic MSCs (GMP-grade)***
- ***Scalable***
- ***Minimally invasive intradermal injection (outpatient)***
- ***ATP-enhanced synergy for niche restoration***
- ***Broad eligibility; rapid availability***

Preclinical evidence
In vivo · In vitro

In vivo

- Males: **Low-dose MSCs** (1×10^6) + ATP → Significantly **increased hair growth,** with the highest proportion of **intense or complete** regrowth by day 21 compared to control **(*p* <0.05).**

Hair growth in AGA mouse model

Control

AGAcell®



Control male



Low-dose AGAcell®



Bran EL, *et al.* Stem Cell Res Ther. 2025;16(1):292.a

- **Histopathology** (day 21): **Increased follicle density** and bulb diameter vs controls.

- A synergistic effect of MSCs and ATP was observed, which exceeded the beneficial effects of high dose MSCs or ATP alone in male mice.

In vitro

- Stability of the product: 96 h, showing a cell viability of 96%.
- Within our CMC process, cells are primed 48 h before and during packaging, leading to upregulated expression of key hair growth–promoting factors—IGF-1 and FGFs—the key signals that support hair-follicle homeostasis and cycling.

Product profile

MoA

- Paracrine signalling to counteract miniaturization.
- Energy co-factor (ATP) to potentiate MSC action.
- Restoration of the hair follicle niche microenvironment.

Formulation

- Cell suspension for intradermal injection: 1×10^6 cells/mL + ATP.

Dose & administration

- Recommended: 1×10^5 cells/cm².
- Treatment area: 30–150 cm² (Norwood III–V).
- Single intradermal (scalp) administration.

Kit & conditioning

- 3–15 prefilled 1 mL syringes (area-adjusted);
  2–8 °C; do not freeze; single-use.
- Shelf life: 96 h from batch release.

ideeea tx® Services

One-stop partner for Cell & Gene Therapies

What we do

- Technical assessment & CMC gap analysis.
- IP strategy & protection.
- GMP manufacturing and batch release.
- Clinical & regulatory support.

Modalities we run

- T cells (CAR-T, TCR, Treg).
- NK.
- iPSCs.
- MSCs.
- EVs.
- Non-cellular products.

Why IDEEEA?

- End-to-end: IND/IMPD → Market.
- Broad cellular expertise (pluripotent, immune, blood-derived).
- Alliance with Cellab CDMO (manufacturing & EU distribution).
- Quality & compliance to international standards.

Choose ideeeatx as your trusted partner — let's bring your therapy to patients faster

Discover more

Follow us

Ideeea Therapeutics S.L.
info@ideeeatx.com
www.ideeeatx.com